Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Misses on EPS, Stock Up 0.57%

Aurinia Pharmaceuticals reported a loss per share of $0.40, which was below expectations. Despite this, the stock saw a slight increase of 0.57%, indicating that investors may have had lower expectations or found other aspects of the report encouraging. The lack of revenue information and management commentary leaves some uncertainty about the company's current performance and future outlook.